Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039653 | 0.85 | PTGDR2 (0.64) | PTGS1PTGS2PTGDR2HTR5A | |
| SCHEMBL6038325 | 0.83 | HTR6 (0.66) | PTGS1PTGDR2BAZ2BCNR1KCNH2 | |
| SCHEMBL7040453 | 0.79 | PTGDR2 (0.50) | PTGS1PTGS2PTGDR2BAZ2BCNR1 | |
| SCHEMBL6336082 | 0.78 | CYP2C9 (0.58) | PTGDR2HTR5A | |
| SCHEMBL31117556 | 0.77 | PTGDR2 (0.62) | PTGDR2BAZ2BCNR1HTR5AMTHFD2 | |
| SCHEMBL7004630 | 0.72 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL10956606 | 0.70 | GAA (0.47) | ALOX5PTGS1PTGS2 | |
| SCHEMBL7036781 | 0.70 | ALDH1A1 (0.38) | PTGDR2CNR1HTR5AMTHFD2KCNH2 | |
| SCHEMBL6335173 | 0.69 | F10 (0.51) | PTGDR2 | |
| SCHEMBL26836992 | 0.69 | ALOX5 (0.58) | ALOX5PTGS1PTGS2BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216378-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | PHARMACIA & UPJOHN CO. | 2003-11-20 | — | — | US | disclosed |
| US-6503899-B2 | Administering to the patient sufffering from anxiety, obesity, depression or stress related diseases an Azepino(4,5-b)pyrano(3,2-e)indoles | PHARMACIA & UPJOHN COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | PHARMACIA & UPJOHN COMPANY | 2002-02-21 | — | — | US | disclosed |
| WO-2002004456-A1 | SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216378-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | NPY5R, HTR5A, IDO1 | ALOX5 558/4885PTGS1 499/4885PTGS2 2058/4885 |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | NPY5R, HTR3C, HTR5A | ALOX5 489/4885PTGS1 761/4885PTGS2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.